Search results
Showing 631 to 645 of 1834 results for carers
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Awaiting development Reference number: GID-TA11741 Expected publication date: TBC
Awaiting development Reference number: GID-TA11753 Expected publication date: TBC
In development Reference number: GID-TA11803 Expected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
Awaiting development Reference number: GID-TA11782 Expected publication date: TBC
Awaiting development Reference number: GID-TA11743 Expected publication date: TBC
Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]
Awaiting development Reference number: GID-TA11692 Expected publication date: TBC
Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]
Awaiting development Reference number: GID-TA11755 Expected publication date: TBC
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]
Awaiting development Reference number: GID-TA11325 Expected publication date: TBC
This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.
In development Reference number: GID-TA11229 Expected publication date: TBC
Awaiting development Reference number: GID-TA11040 Expected publication date: TBC
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.